ELUSYS BEGINS TRIAL OF ANTHRAX TREATMENT

Elusys has launched a trial for the anthrax treatment Anthim, which was granted fast-track status by the FDA in May. The Phase I, randomized, placebo-controlled, double-blind, dose-escalation study is designed to determine the safety, tolerability and pharmacokinetics of a single dose of Anthim in healthy volunteers.

Anthim is a high-affinity monoclonal antibody that targets the protective antigen component of anthrax, blocking the bacteria's ability to form deadly toxins. In preclinical studies, Anthim demonstrated efficacy at lower doses than other drugs in development.